The US Food and Drug Administration has approved Enspryng (satralizumab) for adults with thyroid eye disease, Roche announced on October 16. The interleukin 6 receptor inhibitor becomes, in Roche’s words, the first and only at home subcutaneous treatment option for the condition: patients or caregivers can administer it after training from a healthcare provider, with dosing every four weeks during the maintenance phase.
The approval rests on the Phase 3 SatraGO-1 and SatraGO-2 studies in 258 patients with active, moderate to severe or chronic disease, and the evidence is split. SatraGO-1 did not meet its prespecified primary efficacy endpoint at week 24. SatraGO-2 did hit: 52.9 percent of Enspryng patients achieved a proptosis response, a reduction in eye bulging, against 23.4 percent on placebo, and diplopia, or double vision, was reduced in 60.7 percent against 25.8 percent. Roche reported no new safety signals, consistent with the drug’s existing profile.
Thyroid eye disease is a rare autoimmune condition affecting about 155 in every 100,000 people in the United States, which can cause facial disfigurement and sight threatening complications if untreated. Enspryng was first approved in 2020 for neuromyelitis optica spectrum disorder, so this is a label expansion for an established antibody, not a new molecular launch, and it arrives after a priority review.
The commercial question is positioning. Rival treatments in thyroid eye disease are infusion based, so an at home injection every four weeks is a real practical advantage, but prescribers will weigh it against a pivotal package in which one of two trials missed. Roche has a further Enspryng catalyst ahead: the drug is under priority review for MOGAD, with a decision expected on January 10, 2027.